We compared the efficacy and tolerability of cispatin and 5-fluorouracil (5-FU) with and without bevacizumab as neoadjuvant therapy for patients with resectable esophageal cancer in retrospective analysis.Patients and Methods:The files of 65 patients with resectable esophageal squamous-cell carcinoma or adenocarcinoma who received neoadjuvant therapy (37 group A: cisplatin 80 mg/m2 infusion day 1 followed by 5-FU 1000 mg/m296-hour continuous infusion days 1-4 separated by 3-week interval;28 group B: two 4-day cycles of bevacizumab 7.5 mg/kg followed by the same cisplatin plus 5-FU schedule) were reviewed and the outcomes of the groups were compared.Results:There was no statistically significant difference between group A and B in response rate (30% vs 39%, p=0.25), R0 resection rate (44% vs 43%), p=0.8), and median overall survival ([OS] 23 vs.17 months, p=0.45).Median OS was longer in responding patients in group A than group B (32 vs.18 months, p=0.05).During the postoperative period,no patients died in group A but two patients died in group B.Conclusions: Adding bevacizumab to cisplatin plus 5-FU neoadjuvant chemotherapy did not improve the R0 resection rate or OS in this group of patients with resectable esophageal cancer.